教育背景

1978-1983 上海医科大学 学士

1983-1986 中国医学科学院北京协和医院 住院医师

1986-1990 美国迈阿密大学医学院 博士

工作经历

1991-1993 美国国立犹太免疫与呼吸医学中心， 博士后

1994-1998 华盛顿大学病理系检验医学部， 高级专科住院医生

1998-2005 芝加哥大学病理学系和免疫学会， 助理教授

2005-2015 芝加哥大学病理学系和免疫学会， 终身教授

2015-2021 美国德克萨斯大学西南医学中心病理与免疫学， 教授

2021-2024 清华大学医学院，讲席教授

2021-至今 清华大学基础医学院， 肿瘤中心主任， 讲席教授

研究领域

研究肿瘤免疫的细胞及分子机制和肿瘤靶向治疗的新策略。

本实验室长期关注于肿瘤免疫微环境的研究，建立了多种小鼠及人源化小鼠肿瘤模型，从细胞到分子深入研究肿瘤免疫微环境的相互作用机制，并在传统肿瘤疗法依赖并影响免疫系统方面取得了重大进展。同时，利用先进的蛋白质工程技术，开发新一代的免疫治疗的新抗体新分子，为肿瘤靶向治疗新策略提供理论基础和实验依据。

科学贡献

近年来，主持开发了新一代双特异性抗体、融合蛋白、细胞因子前药和抗体前药用于肿瘤免疫治疗，研究靶向药物、局部辐射、肿瘤靶向抗体对肿瘤微环境，免疫系统的调控机制，发展免疫协同治疗新策略，很多已应用于不同阶段的临床试验，展现出了极大的应用前景和价值。开发的新一代蛋白疫苗已用于临床。现已在Science，Nature，Nature Medicine等领域内顶尖学术刊物发表260多篇高水平的学术研究论文，文章被引用次数超过50,000余次，H-index 115，并在2019-2023年入选Clarivate全球“高被引科学家”，成为少数同时在医学和基础科研领域都取得突出成绩的医生和科学家；在肿瘤免疫学领域内尤其具有很高的声望和影响力，是药物、放疗和靶向治疗对免疫细胞及分子机制研究的开拓者。

荣誉奖励

2015 CPRIT高级研究员奖

2015 芝加哥大学和UTSW特聘教授

2005 中国科学院客座教授、顾问

1999 NMSS奖获得者

1997 NIAID临床研究者奖（K08）

1997 ACLPS青年研究员奖

1996 ACLPS青年研究员奖

1991 霍华德休斯医学研究所医师科学家奖学金

代表性论文

1.Tumbath S, Jiang L, Li X, Zhang T, Zahid KR, Zhao Y, Zhou H, Yin Z, Lu T, Jiang S, Chen Y, Chen X, Fu YX*, Huang X. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers. Oncoimmunology. 2024 Jun 4;13(1):2363000.

2.Zou Z, Shen J, Xue D, Li H, Xu L, Cao W, Wang W, Fu YX*, Peng H. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses. Nat Commun. 2024 Jun 3;15(1):4701.

3.Bugno J, Wang L, Yu X, Cao X, Wang J, Huang X, Yang K, Piffko A, Chen K, Luo SY, Naccasha E, Hou Y, Fu S, He C, Fu YX, Liang HL, Weichselbaum RR. Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance. Clin Cancer Res. 2024

4.Wang W, Fu YX*. Promises and challenges of organoids: From humanized to human derived.Cell Stem Cell. 2024 Mar 7;31(3):281-282.

5.Huang J, Zhang X, Xu H, Fu L, Liu Y, Zhao J, Huang J, Song Z, Zhu M, Fu YX, Chen YG, Guo X. Intraepithelial Lymphocytes Promote Intestinal Regeneration through CD160/HVEM Signaling. Mucosal Immunol. 2024 Feb 8:S1933-0219(24)00008-4.

6.Liu G, Ma N, Cheng K, Feng Q, Ma X, Yue Y, Li Y, Zhang T, Gao X, Liang J, Zhang L, Wang X, Ren Z, Fu YX, Zhao X, Nie G. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat Nanotechnol. 2023 Dec 5

7.Wang J, Li S, Wang M, Wang X, Chen S, Sun Z, Ren X, Huang G, Sumer BD, Yan N, Fu YX, Gao J. STING licensing of type I dendritic cells potentiates antitumor immunity. Sci Immunol. 2024 Feb 16;9(92):eadj3945.

8.Huang Y, Lu C, Wang H, Gu L, Fu YX*, Li GM. DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nat Commun. 2023 Aug 28;14(1):5246

9.Facts and hopes on chimeric cytokine agents for cancer immunotherapy. Ren Z, Zhang X, Fu YX. Clin Cancer Res. 2024 Jan 8. doi: 10.1158/1078-0432.

10.Huang Y, Lu C, Wang H, Gu L, Fu YX*, Li GM. DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nat Commun. 2023 Aug 28;14(1):5246.

11.Wang X, Liu L, Yue T, Sun Z, Bae J, Tseng KF, Zhang A, Qiao J, Fu YX*. Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells. Signal Transduct Target Ther. 2023 Jul 12;8(1):268.

12.Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX*, Riggs AD, Martin PJ, Feng R, Zeng D. Share. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023， 120(16):e2205085120

13.Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX*, Riggs AD, Martin PJ, Feng R, Zeng D. Share. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023， 120(16):e2205085120

14.He Q, Sun S, Chen X, Hu Z, Zhang Y, Peng H, Fu YX*, Yang J, Chen L. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages J Clin Med. 2022 Dec 24;12(1):146

15.Peng H, Fu YX*. Towards developing a variant-proof SARS-CoV-2 vaccine. Cell Res. 2023. 33(1):5-6

16.Meng CY, Sun S, Liang Y, Xu H, Zhang C, Zhang M, Wang FS, Fu YX*, Peng H. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023. 72(8):1544-1554，

17.Bae J, Liu L, Moore C, Hsu E, Zhang A, Ren Z, Sun Z, Wang X, Zhu J, Shen J, Qiao J, Fu YX*. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer. Nat Cell Biol. 2022 24(12):1754-1765.

18.He Q, Sun S, Chen X, Hu Z, Zhang Y, Peng H, Fu YX, Yang J, Chen L. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages. J Clin Med. 2022 Dec 24;12(1):146.

19.Shen J, Zou Z, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H, Fu YX*. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med. 2022 Dec 5;219(12): e20220745.

20.Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, Li S, Liang H, Xu Z, Zheng W, Wang L, Wang J, Huang X, Ting JPY, Fu YX, Lin W, Weichselbaum RR. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol. 2022 Dec;17(12):1322-1331.

21.Moore C, Bae J, Liu L, Li H, Fu YX*, Qiao J. Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. JCI Insight. 2022 Sep 8;7(17):e159479

22.Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang J, Wilhelm J, Li S, Song J, Li W, Sun Z, Sumer BD, Li B, Fu YX*, Gao J. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun. 2022 Sep 6;13(1):4981.

23.Zhang Z, He Q, Zhao W, Li Y, Yang J, Hu Z, Chen X, Peng H, Fu YX, Chen L, Lu L. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. J Clin Med. 2022 Jul 18;11(14):4164.

24.Li F, Zhang H, Wang W, Yang P, Huang Y, Zhang J, Yan Y, Wang Y, Ding X, Liang J, Qi X, Li M, Han P, Zhang X, Wang X, Cao J, Fu YX*, Yang X. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies. Nat Commun. 2022 Jul 26;13(1):4334.

25.Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX*, Hanker AB, Arteaga CL. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunol Res. 2022 Jul 1;10(7):829-843

26.Lin Y, Sun J, Cao X, Wang X, Chen X, Xu H, Zhao J, Fu YX*, Peng H. Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discov. 2022 May 10;8(1):43.

27.Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1 + CD8 T cells. Cell Rep Med. 2022 Mar 15;3(3):100554.

28.Liu L, Chen J, Zhang H, Ye J, Moore C, Lu C, Fang Y, Fu YX*, Li B. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nat Cancer. 2022 Apr;3(4):437-452

29.Peng H, Fu YX*. Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine. Cell Res. 2022 Apr;32(4):331-332.

30.Ren Z, Zhang A, Sun Z, Liang Y, Ye J, Qiao J, Li B, Fu YX*. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity。J Clin Invest。 2022 Feb 1;132(3):e153604.

31.Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y, Cao S, Wang Y, Fu YX*, Peng H. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors。Sci Immunol 2022 Jan 7;7(67):eabi6899

32.Song S, Zhou B, Cheng L, Liu W, Fan Q, Ge X, Peng H, Fu YX, Ju B, Zhang Z. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Virol J. 2022 Jan 4;19(1):2.

33.Sun S, Chen X, Lin J, Ai J, Yang J, Hu Z, Fu YX*, Peng H. Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell Discov. 2021.7(1):114.

34.Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J, Fu YX*. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat Biomed Eng. 2021 5(11):1261-1273.

35.Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, Yang H, Yu X, Yang K, Bugno J, Ding X, Vokes E, Fu YX*. Weichselbaum RR, Liang HL All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 Jun 15;6(60):eaba8426.

36.Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu EJ, Zhu J, Zhou J, Fu YX*. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021 Oct 7;12(1):5866.

37.Hannan R, Mohamad O, Diaz de Leon A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga Y, Courtney K, Cantarel B, Wakeland EK, Fu YX, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021 Sep 22:clincanres.2083.2021.

38.Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, Fu YX*, Peng H. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Aug 10. doi: 10.1038/s41422-021-00543-4.

39.Zhang A, Ren Z, Tseng KF, Liu X, Li H, Lu C, Cai Y, Minna JD, Fu YX*. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Sci Transl Med. 2021 Aug 4;13(605):eabg8693.

40.Rodriguez AB, Peske JD, Woods AN, Leick KM, Mauldin IS, Meneveau MO, Young SJ, Lindsay RS, Melssen MM, Cyranowski S, Parriott G, Conaway MR, Fu YX, Slingluff CL Jr, Engelhard VH. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 2021 Jul 20;36(3):109422

41.Sun S, Cai Y, Song TZ, Pu Y, Cheng L, Xu H, Sun J, Meng C, Lin Y, Huang H, Zhao F, Zhang S, Gao Y, Han JB, Feng XL, Yu DD, Zhu Y, Gao P, Tang H, Zhao J, Zhang Z, Yang J, Hu Z, Fu YX, Zheng YT, Peng H. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Sep;31(9):1011-1023.

42.Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, Fu YX*. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021, 12(1):2768.

43.Han C, Godfrey V, Liu Z, Han Y, Liu L, Peng H, Weichselbaum RR, Zaki H, Fu YX*. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Sci Immunol. 2021, 6(59):eabc6998.

44.Moore C, Hsu CC, Chen WM, Chen BPC, Han C, Story M, Aguilera T, Pop LM, Hannan R, Fu YX, Saha D, Timmerman R Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2021 Mar 29:S0360-3016(21)00309-6.

45.He Y, Fu L, Li Y, Wang W, Gong M, Zhang J, Dong X, Huang J, Wang Q, Mackay CR, Fu YX, Chen Y, Guo X. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab. 2021 33(5):988-1000.e7.

46.Liang Y, Hannan R, Fu YX*. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. Clin Cancer Res. 2021, doi: 10.1158/1078-0432

47.Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-X L destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021, 12(1):1281.

48.Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX*, Weichselbaum RR. Sci Transl Med. 2021,13(578):eaba7308.

49.Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, Li W, Wang J, Cholka A, Fu YX, Sumer BD, Yu H, Gao J. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat Biomed Eng. 2021, 5(5):455-466.

50.Zhang H, Li F, Cao J, Wang X, Cheng H, Qi K, Wang G, Xu K, Zheng J, Fu YX*, Yang X. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Sci Transl Med. 2021 13(578):eaba7308.

51.Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX*, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 Mar 1;218(3):e20201915.

52.Son YM, Cheon IS, Wu Y, Li C, Wang Z, Gao X, Chen Y, Takahashi Y, Fu YX, Dent AL, Kaplan MH, Taylor JJ, Cui W, Sun J. Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Sci Immunol. 2021 Jan 8;6(55):eabb6852.

53.Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, Zhang Y, Ortega J, Zhang J, Siteni S, Chen M, Gu L, Shay JW, Davis AJ, Chen ZJ, Fu YX*, Li GM. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell. 2020 39(1):109-121

54.Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T, Stephens D, Zhang H, Zhu J, Yang M, Ren Z, Liang Y, Liu Z, Han C, Liu L, Cao X, Zhang A, Qiao J, Batten K, Chen M, Castrillon DH, Wang T, Li B, Diaz LA Jr, Li GM, Fu YX*. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell. 2020 39(1):96-108.

55.Han C, Zhang A, Liu Z, Moore C, Fu YX*. Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. Oncogene. 2020 40(5):885-898

56.Wang Y, Luo M, Chen Y, Wang Y, Zhang B, Ren Z, Bao L, Wang Y, Wang JE, Fu YX, Luo W, Wang Y. ZMYND8 expression in breast cancer cells blocks T-lymphocyte surveillance to promote tumor growth. Wang Y, Luo M, Chen Y, Wang Y, Zhang B, Ren Z, Bao L, Wang Y, Wang JE, Fu YX, Luo W, Wang Y. Cancer Res. 1710.2020.

57.Zheng W, Ranoa DRE, Huang X, Hou Y, Yang K, Poli EC, Beckett MA, Fu YX*, Weichselbaum RR. RIG-I-like receptor LGP2 is required for tumor control by radiation therapy. Cancer Res. 2020 Oct 21:canres.2324.2020.

58.Zhang L, Zhang A, Xu J, Qiu C, Zhu L, Qiu C, Fu W, Wang Y, Ye L, Fu YX, Zhao C, Zhang X, Xu J. CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells. Front Immunol. 11:2188; 2020.

59.Rao L, Wu L, Liu Z, Tian R, Yu G, Zhou Z, Yang K, Xiong HG, Zhang A, Yu GT, Sun W, Xu H, Guo J, Li A, Chen H, Sun ZJ, Fu YX, Chen X. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis Nat Commun. 2020 Sep 30;11(1):4909.

60.Suresh S, Chen B, Zhu J, Golden RJ, Lu C, Evers BM, Novaresi N, Smith B, Zhan X, Schmid V, Jun S, Karacz CM, Peyton M, Zhong L, Wen Z, Sathe AA, Xing C, Behrens C, Wistuba II, Xiao G, Xie Y, Fu YX, Minna JD, Mendell JT, O’Donnell KA. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer. 2020 1(5):533-545.

61.Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu YX*, Tang H. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020 Sep 24;11(1):4835

62.Han C, Fu YX*. β-Catenin regulates tumor-derived PD-L1. J Exp Med 2020 Nov 2;217(11):e20200684

63.Beshnova D, Ye J, Onabolu O, Moon B, Zheng W, Fu YX, Brugarolas J, Lea J, Li B. De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Sci Transl Med 12(557):eaaz3738, 2020

64.Peng H, Fu YX*. The Inhibitory PVRL1/PVR/TIGIT Axis in Immune Therapy for Hepatocellular Carcinoma. Gastroenterology S0016-5085(20)34822-8, 2020

65.Wang W, Li Y, Hao J, He Y, Dong X, Fu YX*, Guo X*. The Interaction between Lymphoid Tissue Inducer-Like Cells and T Cells in the Mesenteric Lymph Node Restrains Intestinal Humoral Immunity, Cell report 32(3):107936. 2020

66.Mender I, Zhang A, Ren Z, Han C, Deng Y, Siteni S, Li H, Zhu J, Vemula A, Shay JW, Fu YX*. Telomere Stress Potentiates Host STINT Dependent Anti-Tumor Immunity Cancer Cell S1535-6108(20)30270-1. 2020

67.Li HD, Lu C, Zhang H, Hu Q, Zhang J, Cuevas IC, Sahoo SS, Aguilar M, Maurais EG, Zhang S, Wang X, Akbay EA, Li GM, Li B, Koduru P, Ly P, Fu YX*, Castrillon DH. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight 2020 Jul 23;5(14):138829.

68.Zuo H, Yang D, Yang Q, Tang H, Fu YX*, Wan Y. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun. 2020 Mar 27;11(1):1578. PMC7101362

69.Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, Shen A, Wang Y, Tang H, Fu YX*, Peng H. Targeting Tumors With IL-21 Reshapes the Tumor Microenvironment by Proliferating PD-1intTim-3-CD8+ T Cells JCI Insight. 2020 Apr 9;5(7):e132000.

70.Zhang H, Liu L, Zhang J, Chen J, Ye J, Shukla S, Qiao J, Zhan X, Chen H, Wu CJ, Fu YX*, Li B. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clin Cancer Res. 2020 26(6):1359-1371.

71.Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, Wang Z, Zhu P, Peng H, Yan X, Li W, Fu YX*, Zhu M. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020.

72.Shi Y, Zheng W, Yang K, Harris KG, Ni K, Xue L, Lin W, Chang EB, Weichselbaum RR, Fu YX*. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020 217(5):e20192282.

73.Liu Z, Fu YX. Chemotherapy Induces Cancer-Fighting B Cells. Cell. 2020 Mar 19;180(6):1037-1039.

74.Zuo H, Yang D, Yang Q, Tang H, Fu YX*, Wan Y. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun. 2020 11(1):1578.

75.Han C, Liu Z, Zhang Y, Shen A, Dong C, Zhang A, Moore C, Ren Z, Lu C, Cao X, Zhang CL, Qiao J, Fu YX*. Tumor Cells Suppress Radiation-Induced Immunity by Hijacking Caspase 9 Signaling. Nat Immunol. 2020, .21(5):546-554.

76.Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, Shen A, Wang Y, Tang H, Fu YX*, Peng H*. Targeting Tumors With IL-21 Reshapes the Tumor Microenvironment by Proliferating PD-1intTim-3-CD8+ T Cells. JCI Insight. 2020 Apr 9;5(7):132000.

Complete list of publications:

All publications in Chinese Medical Journals are not included

https://www.ncbi.nlm.nih.gov/pubmed/?term=yang-xin+fu

https://scholar.google.com/citations?user=UU4QhnoAAAAJ&hl=en